TY  - JOUR
AU  - Koerber, Stefan A
AU  - Boesch, Johannes
AU  - Kratochwil, Clemens
AU  - Schlampp, Ingmar
AU  - Ristau, Jonas
AU  - Winter, Erik
AU  - Zschaebitz, Stefanie
AU  - Hofer, Luisa
AU  - Herfarth, Klaus
AU  - Kopka, Klaus
AU  - Holland-Letz, Tim
AU  - Jaeger, Dirk
AU  - Hohenfellner, Markus
AU  - Haberkorn, Uwe
AU  - Debus, Juergen
AU  - Giesel, Frederik
TI  - Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma.
JO  - Cancers
VL  - 13
IS  - 7
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2021-00794
SP  - 1508
PY  - 2021
N1  - #LA:E060#
AB  - Men diagnosed with aggressive prostate cancer are at high risk of local relapse or systemic progression after definitive treatment. Treatment intensification is highly needed for that patient cohort; however, no relevant stratification tool has been implemented into the clinical work routine so far. Therefore, the aim of the current study was to analyze the role of initial PSMA-PET/CT as a prediction tool for metastases. In total, 335 men with biopsy-proven prostate carcinoma and PSMA-PET/CT for primary staging were enrolled in the present, retrospective study. The number and site of metastases were analyzed and correlated with the maximum standardized uptake value (SUVmax) of the intraprostatic, malignant lesion. Receiver operating characteristic (ROC) curves were used to determine sensitivity and specificity and a model was created using multiple logistic regression. PSMA-PET/CT detected 171 metastases with PSMA-uptake in 82 patients. A statistically significant higher SUVmax was found for men with metastatic disease than for the cohort without distant metastases (median 16.1 vs. 11.2; p < 0.001). The area under the curve (AUC) in regard to predicting the presence of any metastases was 0.65. Choosing a cut-off value of 11.9 for SUVmax, a sensitivity and specificity (factor 1:1) of 76.0
KW  - PET (Other)
KW  - PSMA (Other)
KW  - intraprostatic SUV (Other)
KW  - metastases (Other)
KW  - prostate cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:33805971
DO  - DOI:10.3390/cancers13071508
UR  - https://inrepo02.dkfz.de/record/168283
ER  -